Protriptyline

證據等級: L5

預測適應症: 5 個

Protriptyline: From Tricyclic Antidepressant to Attention-Deficit Hyperactivity Disorder, Inattentive Type

One-Sentence Summary

Protriptyline is a tricyclic antidepressant (TCA); its original indication text and detailed mechanism of action are not available in this evidence pack. The TxGNN model predicts it may be effective for Attention-Deficit Hyperactivity Disorder, Inattentive Type, with 0 clinical trials and 0 publications directly supporting this specific subtype — evidence is currently mechanistic/extrapolated only.

Quick Overview

Item	Content
Original Indication	Not specified in source data (drug class noted as Tricyclic Antidepressant, TCA)
Predicted New Indication	Attention-Deficit Hyperactivity Disorder, Inattentive Type
TxGNN Prediction Score	99.95%
Evidence Level	L4
US Market Status	Not Marketed
Number of NDAs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available (flagged as a data gap). Based on the mechanistic rationale provided, Protriptyline is a tricyclic antidepressant (TCA) that primarily inhibits norepinephrine (NE) reuptake with minimal serotonergic activity, giving it a pharmacological profile similar to desipramine and nortriptyline.

NE signaling is known to regulate prefrontal executive function and attention. TCAs with this profile have historically been used as second-line options for ADHD, particularly in patients with poor stimulant response or comorbid tics, and have also shown mild alerting/activating effects (historically used in narcolepsy). This gives biological plausibility to the TxGNN prediction for the inattentive ADHD subtype.

However, this specific mechanistic link has not yet been tested directly: no clinical trials or literature target the inattentive subtype specifically. A related, lower-ranked prediction in this evidence pack — general ADHD (not the inattentive subtype) — is supported by one retrospective naturalistic cohort study (PMID 8936915, tier 2 evidence), which lends indirect support to the drug class’s plausibility for attention-related symptoms, but does not directly validate the inattentive-subtype prediction shown here.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available for this specific prediction (inattentive-type ADHD).

Note: A related but distinct prediction in this evidence pack — general ADHD — is supported by one retrospective naturalistic study (PMID 8936915, Wilens et al., 1996, J Am Acad Child Adolesc Psychiatry), evaluating protriptyline in children/adolescents with ADHD. This does not directly confirm efficacy for the inattentive subtype specifically.

US Market Information

No marketing authorization records are available. Per regulatory data, this drug is currently not marketed (0 licenses on file).

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: While the TxGNN prediction score is very high (99.95%), there is no direct clinical trial or literature evidence for this specific ADHD subtype, and the mechanistic rationale is extrapolated rather than confirmed. Critical safety data (TFDA warnings/contraindications) is also flagged as a blocking gap, preventing any S1 safety evaluation.

To proceed, the following is needed:

TFDA label warnings and contraindications (blocking gap — required before any safety assessment)
Confirmed mechanism of action data via DrugBank
Subtype-specific clinical evidence (trials or literature) for inattentive-type ADHD, rather than relying on general ADHD extrapolation
Expert/ontology review to confirm the “inattentive type” disease mapping is clinically meaningful and distinct from general ADHD in this context
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.